Further analysis of data from an international trial of two investigational drugs in people in the early stages of a rare, inherited form of Alzheimer’s disease has demonstrated that one of the drugs had a positive impact on biomarkers of the disease. The study (ClinicalTrials.gov Identifier: NCT01760005) is a phase 2/3 trial led by Washington […]
Category: DIAN-TU Research Updates
Investigational drugs didn’t slow memory loss, cognitive decline in rare, inherited Alzheimer’s, initial analysis indicates (Links to an external site)
Top-line data reported from international trial
A message from Dr. Bateman to DIAN-TU trial participants
Video
Update on the DIAN-TU-001 TRIAL: Janssen BACE Inhibitor (JNJ-54861911/atabecestat) DRUG ARM DISCONTINUATION
Update to the May 25th announcement found on Janssen’s website
DIAN-TU-001 INTERIM ANALYSIS
Notice to DIAN-TU Investigational Sites and Participants
2015 Update
The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) has completed the first stage of participant enrollment in the first Alzheimer’s prevention trial for autosomal dominant Alzheimer’s disease (ADAD), also referred to as early-onset Alzheimer’s disease. The goal of the first stage of the study is to determine the biomarker and cognitive effects of two different […]